Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor - Regional Cancer Care Associates LLC

Clinical Trials

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung
Locations
Hackensack
Sponsor
Mirati
Protocol Number
265-109
Cancer Diagnosis
To Learn More Call
201-510-0910